Clinical Trial Update: Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the efficacy and safety of Recombinant Somatroipn in patients with Growth Hormone Deficiency; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Recombinant Somatroipn (somatroipn)

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Growth Hormone Deficiency | Phase 3 | Status: COMPLETED